Dr. Can Sheng | Dementia Award | Best Researcher Award

Dr. Can Shen, The Affiliated Hospital of Jining Medical University, China

Can Sheng is a Professor at the Department of Neurology, the Affiliated Hospital of Jining Medical University in China. She obtained her M.D. from the Department of Neurology, Xuanwu Hospital of Capital Medical University, under the mentorship of Professor Ying Han. Her research focuses on the gut microbiome and multi-modal neuroimaging biomarkers in Alzheimer’s disease (AD) spectrum. Can Sheng is the Principal Investigator of several prestigious grants, including from the National Natural Science Foundation of China and the Natural Science Foundation of Shandong Province. She has authored over 30 peer-reviewed articles in renowned journals such as Alzheimer’s & Dementia and Alzheimer’s Research & Therapy, contributing significantly to the field. Can Sheng is also an active member of the Beijing Cognitive Neuroscience Society.

🌐 Professional Profile:

Orcid

🎓 Education and Qualifications:

• Xuan Wu Hospital of the Capital Medical University: Completed residency in Neurology from September 2019 to July 2022.
• Xuan Wu Hospital of the Capital Medical University: Previously, from September 2013 to July 2016, pursued further education in Neurology.
• Jining Medical University: Completed undergraduate studies from September 2008 to July 2013.

🔬 Professional Activities:

• Beijing Cognitive Neuroscience Society: Serving as a Member of the Council since January 1, 2024. Based in Beijing, China.

🌐 Research and Funding:

• Awarded funding from the National Natural Science Foundation of China for the project “Regulatory Mechanism of Intestinal Microorganism in Intervening Mild Cognitive Impairment based on Magnetic Resonance Imaging Techniques.”

Publication Top Notes:

1. The link between gut microbiome and Alzheimer’s disease: From the perspective of new revised criteria for diagnosis and staging of Alzheimer’s disease

2. An integrated neuroimaging-omics approach for the gut-brain communication pathways in Alzheimer’s disease

3. Alterations of gut microbiota are associated with brain structural changes in the spectrum of Alzheimer’s disease: the SILCODE study in Hainan cohort

4. Alterations in Peripheral Metabolites as Key Actors in Alzheimer’s Disease

5. Generative adversarial network constrained multiple loss autoencoder: A deep learning‐based individual atrophy detection for Alzheimer’s disease and mild cognitive impairment